Sarepta Therapeutics Announces Fourth Quarter and Full Year 2013 Financial Results and Recent Corporate Developments

[at noodls] – Clarity on Eteplirsen Confirmatory Trial Design Expected in Coming Weeks 2014 Financial Guidance of $110-120 Million in Non-GAAP Operating Loss Cash and Other Investments of $265 Million at Year End 2013 … more

View todays social media effects on SRPT

View the latest stocks trending across Twitter. Click to view dashboard

See who Sarepta is hiring next, click here to view